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iDeBACKGROUND Despite the well-established beneﬁts of secondary cardiovascular prevention, the importance of
concurrent medical therapy in clinical trials of coronary revascularization is often overlooked.
OBJECTIVES The goal of this study was to assess compliance with guideline-directed medical therapy (GDMT) in
clinical trials and its potential impact on the comparison between percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG).
METHODS The Cochrane Central Register of Controlled Trials and MEDLINE were searched from 2005 to August
2017. Clinical trial registries and reference lists of relevant studies were also searched. Randomized controlled trials
comparing PCI with drug-eluting stents versus CABG and reporting medical therapy after revascularization were
included. The study outcome was compliance with GDMT, deﬁned as the following: 1) any antiplatelet agent plus
beta-blocker plus statin (GDMT1); and 2) any antiplatelet agent plus beta-blocker plus statin plus angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker (GDMT2). Data collection and analysis were performed according to
the methodological recommendations of The Cochrane Collaboration.
RESULTS From a total of 439 references, 5 trials were included based on our inclusion and exclusion criteria. Overall,
compliance with GDMT1 was low and decreased over time from 67% at 1 year to 53% at 5 years. Compliance with GDMT2
was even lower and decreased from 40% at 1 year to 38% at 5 years. Compliance with both GDMT1 and GDMT2 was
higher in PCI than in CABG at all time points. Meta-regression suggested an association between lower use of GDMT1 and
adverse clinical outcomes in PCI versus CABG at 5 years.
CONCLUSIONS Compliance with GDMT in contemporary clinical trials remains suboptimal and is signiﬁcantly lower
after CABG than after PCI, which may inﬂuence the comparison of clinical trial endpoints between those study groups.
(J Am Coll Cardiol 2018;71:591–602) © 2018 by the American College of Cardiology Foundation.N 0735-1097/$36.00 https://doi.org/10.1016/j.jacc.2017.11.068
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592G uideline-directed medical therapy(GDMT) is recommended byevidence-based guidelines for all
patients with coronary artery disease (CAD).
In addition to being considered the ﬁrst line
of treatment for patients with stable CAD,
GDMT as secondary prevention after coro-
nary revascularization with either percuta-
neous coronary intervention (PCI) or
coronary artery bypass grafting (CABG) (1,2)
is associated with a signiﬁcant reduction in
mortality and myocardial infarction (MI)
risk (3). Moreover, GDMT alone may achieve
a greater reduction in mortality than the
choice of revascularization strategy (4).
However, currently available evidence
suggests that compliance with GDMT remains poor
after coronary revascularization, particularly after
CABG (5–8) and in patients with comorbidities such as
chronic renal disease. This poor compliance further
increases patients’ already higher risk of adverse out-
comes (9). Moreover, randomized controlled trials
(RCTs) of coronary revascularization, which are the
primary source of evidence to guide contemporary
clinical practice, often provide scant information
regarding concurrent medical treatment (10). There-
fore, whether the poor compliance with GDMT re-
ported in population-based studies is also reﬂected in
clinical trials and to what extent different compliance
rates inﬂuence clinical outcomes between PCI and
CABG remain unknown.
The aims of the present study were as follows: 1) to
analyze compliance with GDMT in landmark clinical
trials of coronary revascularization; 2) to compare
compliance with GDMT in PCI versus CABG; and 3) to
assess its potential association with clinical trial
outcomes.SEE PAGE 603METHODS
STUDY DESIGN. We performed a systematic review
and meta-analysis according to recommendations of
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement (11) and The Cochrane
Collaboration (12).
SEARCH STRATEGY. The Cochrane Central Register
of Controlled Trials in the Cochrane Library andew York, New York; and the kCentro Nacional de Investigaciones
d research support from Amgen. All other authors have report
this paper to disclose. Hartzell V. Schaff, MD, served as Guest E
received September 5, 2017; revised manuscript received NovemMEDLINE in PubMed were searched from 2005 to
August 2017. This search was complemented by hand-
searching reference lists of relevant studies and
clinical trial registries (August 2017). We did not apply
limits by publication language, status, or date.
Further details on search strategies are described in
the protocol and the Online Appendix.
SELECTION CRITERIA. RCTs comparing PCI with
drug-eluting stents versus CABG in patients with CAD
were included in the study. (Inclusion and exclusion
criteria are speciﬁed in the Online Appendix.)
DEFINITION OF OUTCOMES. GDMT was deﬁned in 2
different categories: 1) GDMT1, a combination of any
antiplatelet agent, beta-blocker, and statin; and
2) GDMT2, a combination of any antiplatelet agent,
beta-blocker, statin, and angiotensin-converting
enzyme (ACE) inhibitor and/or angiotensin receptor
blocker (ARB).
STUDY SELECTION AND DATA COLLECTION. Two
review authors independently screened all identiﬁed
references according to pre-deﬁned inclusion criteria.
Full-text articles of those references were retrieved
and reviewed for ﬁnal inclusion according to pre-
speciﬁed inclusion and exclusion criteria. Disagree-
ments were resolved by consensus.
Authors of the included trials were invited to pro-
vide individual patient data for the main classes
of GDMT: aspirin, adenosine diphosphate P2Y12-
receptor inhibitor, beta-blocker, statin, and ACE in-
hibitor and/or ARB. Data regarding clinical outcomes
were obtained from published trial reports. One
author collated outcome data into a master database
and performed quality assessment, with a second
author verifying its accuracy.
Compliance rates were calculated for individual
drug classes and GDMT1 and GDMT2 as the number
of patients prescribed each drug divided by the
total number of patients with follow-up at each
speciﬁc time point. Analysis was performed for pa-
tients undergoing PCI and CABG by computing
compliance rates for each group. We used the
absolute risk reduction as the effect measure, and
differences in compliance rates and clinical out-
comes were calculated by subtracting those of CABG
from those of PCI. The time points selected for
analysis were as follows: discharge, 1 year, 3 years,
and 5 years.Cardiovasculares (CNIC), Madrid, Spain. Dr. Farkouh
ed that they have no relationships relevant to the
ditor for this paper.
ber 26, 2017, accepted November 28, 2017.
TABLE 1 Summary of Large, Multicenter RCTs Comparing PCI Versus CABG in Patients Undergoing Revascularization for Complex CAD
Trial (Ref. #) Date Site Study Period Population
Number of
Patients Interventions Primary Endpoint
Follow-Up
(yrs)
Outcome*
PCI
(%)
CABG
(%) p Value
SYNTAX (27) 2013 85 centers in the
United States
and Europe
2005–2007 3-VD or LMS 1,800 PCI with ﬁrst-generation
paclitaxel-eluting stent
vs. CABG (1:1 ratio)
All-cause death, stroke,
myocardial infarction,
and repeat
revascularization
1 17.8 12.4 0.002
5 37.3 26.9 <0.001
FREEDOM (28) 2012 140 international
centers
2005–2010 Diabetes and
multivessel
coronary artery
disease (3-VD or
LMS)
1,900 PCI with sirolimus- or
paclitaxel-eluting
stents vs. CABG (1:1
ratio)
All-cause death, nonfatal
myocardial infarction,
or nonfatal stroke
2 13.0 11.9 0.005
5 26.6 18.7 0.005
PRECOMBAT
(29)
2015 13 centers in
South Korea
2005–2009 LMS 600 PCI with sirolimus-eluting
stent vs. CABG (1:1
ratio)
All-cause death,
myocardial infarction,
stroke, or ischemia-
driven target-vessel
revascularization
1 8.7 6.7 0.01
5 17.5 14.3 0.26
BEST (30) 2015 27 centers in
East Asia
2008–2013 Multivessel
coronary artery
disease (3-VD or
LMS)
880 PCI with everolimus-
eluting stent vs. CABG
(1:1 ratio)
All-cause death,
myocardial infarction,
or target-vessel
revascularization
2 11.0 7.9 0.32
4.6 (median) 15.3 10.6 0.04
EXCEL (31) 2016 126 centers in
17 countries
2010–2014 LMS with low/
intermediate
SYNTAX scores
1,905 PCI with everolimus-
eluting stent vs. CABG
(1:1 ratio)
All-cause death, stroke,
or myocardial
infarction
3 15.4 14.7 0.98
*Outcome for primary endpoint.
3-VD ¼ 3-vessel disease; BEST ¼ Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery
Disease trial; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; EXCEL ¼ Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
trial; FREEDOM ¼ Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial; LMS ¼ left main stem disease; PCI ¼ percutaneous coronary
intervention; PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial;
RCT ¼ randomized controlled trial; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery trial.
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593RISK OF BIAS ASSESSMENT. Risk of bias of individ-
ual studies was assessed according to the recom-
mendations of The Cochrane Collaboration (12),
taking into account the following items: 1) random
sequence generation (selection bias); 2) allocation
concealment (selection bias); 3) blinding of partici-
pants and personnel (performance bias); 4) blinding
of outcome assessment (detection bias); 5) incom-
plete outcome data addressed (attrition bias); and
6) selective reporting (reporting bias).
STATISTICAL ANALYSIS AND EVIDENCE SYNTHESIS.
Meta-analysis was conducted to assess the pooled
compliance with GDMT in all the trials and to compare
intervention groups (PCI vs. CABG). Outcomes and
effect measures were reported as untransformed pro-
portion and risk difference with 95% conﬁdence
intervals, respectively. The overall meta-analytical
effect size was estimated by using the random
effects model and the restricted maximum likelihood
method. Chi-square Q statistics and I2 statistics were
used to assess heterogeneity. Meta-regression with a
random effects model was performed to assess the
impact of compliance with GDMT on clinical outcomes
at 5 years. Overall trial data (and not individual patient
data) were used, and only trials with 5-year follow-up
were included in meta-regression. All statisticalanalyses were performed using the software Open
MetaAnalyst (13). A p value <0.05 was considered
statistically signiﬁcant for all analyses.
RESULTS
STUDY SELECTION. The study search strategy yiel-
ded 749 references, of which 395 were excluded after
screening. A total of 46 papers were reviewed, and 18
RCTs ultimately met the inclusion criteria. However,
after reviewing the full papers, only 5 were included
for analysis (Online Figure 1).
Thirteen RCTs were excluded:
 MASS II (Medicine, Angioplasty, or Surgery Study)
trial (14) and BARI 2D (Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes) trial (15)
compared medical therapy versus revasculariza-
tion with either PCI or CABG;
 VA CARDS (Coronary Artery Revascularization in
Diabetes trial) (16) had serious methodological
limitations (recruitment was stopped after
enrolling only 25% of the intended sample size);
 SIMA (Stenting versus Internal Mammary Artery
grafting) trial (17), BARI (Bypass Angioplasty
Revascularization Investigation trial) (18), LEMANS
(Left Main Coronary Artery Stenting trial) (19), SoS
FIGURE 1 Compliance With GDMT1, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin, in All Clinical Trials Over Time
0.3 0.4 0.5 0.6 0.7 0.8 0.9
Proportion of Compliance
0.654 (0.632-0.676)
0.628 (0.606-0.650)
0.365 (0.326-0.404)
0.469 (0.436-0.502)
0.825 (0.807-0.842)
SYNTAX
Studies (GDMT1 at discharge)
FREEDOM
PRECOMBAT
BEST
EXCEL
1,138/1,740
1,193/1,900
216/592
413/880
1,519/1,842
0.589 (0.433-0.744)Overall (I2 = 99.51 % , p < 0.001) 4,479/6,954
Compliance
0.3 0.4 0.5 0.6 0.7 0.8 0.9
Proportion of Compliance
0.657 (0.634-0.679)
0.733 (0.711-0.754)
0.381 (0.341-0.420)
0.740 (0.711-0.770)
0.840 (0.824-0.857)
SYNTAX
Studies (GDMT1 at 1 year)
FREEDOM
PRECOMBAT
BEST
EXCEL
1,105/1,683
1,208/1,649
222/583
636/859
1,533/1,824
0.671 (0.518, 0.823)Overall (I2 = 99.51 % , p < 0.001) 4,704/6,598
Compliance
0.3 0.4 0.5 0.6 0.7 0.8 0.9
Proportion of Compliance
0.608 (0.585-0.632)
0.722 (0.696-0.747)
0.434 (0.397-0.471)
0.857 (0.837-0.876)
SYNTAX
Studies (GDMT1 at 3 years)
FREEDOM
BEST
EXCEL
982/1614
851/1179
302/696
1,039/1,213
0.656 (0.480, 0.831)Overall (I2 = 99.48 % , p < 0.001) 3,174/4,702
Compliance
0.2 0.3 0.4 0.5 0.6 0.7 0.8
Proportion of Compliance
0.593 (0.568-0.618)
0.698 (0.653-0.742)
0.313 (0.265-0.361)
SYNTAX
Studies (GDMT1 at 5 years)
FREEDOM
BEST
870/1468
286/410
112/358
0.535 (0.310, 0.759)Overall (I2 = 99.02 % , p < 0.001) 1,268/2,236
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
Compliance
Proportion of compliance calculated as number of patients prescribed guideline-directed medical therapy (GDMT) 1 divided by the total number of patients at each time
point. BEST ¼ Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel
Coronary Artery Disease trial; CI ¼ conﬁdence interval; EXCEL ¼ Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revas-
cularization trial; FREEDOM ¼ Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial;
PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery
Disease trial; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery trial.
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594(Stent or Surgery trial) (20), ERACI II (Argentine
Randomized Study: Coronary Angioplasty With
Stenting Versus Coronary Bypass Surgery Trial) (21),
and CARDia (Coronary Artery Revascularization in
Diabetes) trial (22) used bare-metal stents; The MICASA (Myocardial Injury Following Coro-
nary Artery Surgery Versus Angioplasty) trial (23)
and NOBLE (Nordic-Baltic-British Left Main
Revascularization Study) (24) did not collect data
regarding medical therapy; and
FIGURE 2 Compliance With GDMT2, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin þ ACE Inhibitor or ARB, in All Clinical Trials Over Time
0.1 0.2 0.3 0.4 0.5 0.6
Proportion of Compliance
0.414 (0.391-0.437)
0.519 (0.497-0.542)
0.127 (0.100-0.153)
0.206 (0.179-0.232)
0.422 (0.400-0.445)
SYNTAX
Studies (GDMT2 at discharge)
FREEDOM
PRECOMBAT
BEST
EXCEL
720/1,740
987/1,900
75/592
181/880
778/1,842
0.338 (0.194-0.482)Overall (I2 = 99.44 % , p < 0.001) 2,741/6,954
Compliance
0.1 0.2 0.3 0.4 0.5 0.6 0.7
Proportion of Compliance
0.460 (0.437-0.484)
0.611 (0.587-0.634)
0.137 (0.109-0.165)
0.287 (0.257-0.317)
0.499 (0.477-0.522)
SYNTAX
Studies (GDMT2 at 1 year)
FREEDOM
PRECOMBAT
BEST
EXCEL
775/1,683
1,007/1,649
80/583
250/871
911/1,824
0.399 (0.235-0.563)Overall (I2 = 99.52 % , p < 0.001) 3,023/6,610
Compliance
0.1 0.2 0.3 0.4 0.5 0.6 0.7
Proportion of Compliance
0.442 (0.418-0.466)
0.612 (0.585-0.640)
0.191 (0.162-0.220)
0.548 (0.520-0.576)
SYNTAX
Studies (GDMT2 at 3 years)
FREEDOM
BEST
EXCEL
713/1,614
722/1,179
133/696
665/1,213
0.448 (0.267-0.630)Overall (I2 = 99.44 % , p < 0.001) 2,233/4,702
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
Compliance
0.1 0.2 0.3 0.4 0.5 0.6 0.7
Proportion of Compliance
0.607 (0.560-0.655)
0.106 (0.074-0.138)
SYNTAX
Studies (GDMT2 at 5 years)
FREEDOM
BEST
0.449 (0.423-0.474) 659/1,468
249/410
38/358
0.387 (0.097-0.677)Overall (I2 = 99.55 % , p < 0.001) 946/2,236
Compliance
Proportion of compliance calculated as number of patients prescribed GDMT2 divided by the total number of patients at each time point. ACE ¼ angiotensin-converting
enzyme; ARB ¼ angiotensin receptor blocker; other abbreviations as in Figure 1.
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595 Two other trials were excluded because they did
not collect data regarding medical therapy during
follow-up (25,26).
Therefore, the following trials were included in the
ﬁnal analysis:
 SYNTAX (Synergy Between Percutaneous Coronary
Intervention With TAXUS and Cardiac Surgery)
trial (27); FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease) trial (28);
 PRECOMBAT (Premier of Randomized Comparison
of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main
Coronary Artery Disease) trial (29);
 BEST (Randomized Comparison of Coronary Artery
Bypass Surgery and Everolimus-Eluting Stent
CENTRAL ILLUSTRATION Compliance With GDMT1, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin, for
PCI and CABG
Pinho-Gomes, A.-C. et al. J Am Coll Cardiol. 2018;71(6):591–602.
Difference in compliance calculated by subtracting proportion of compliance in coronary artery bypass grafting (CABG) from proportion of compliance in
percutaneous coronary intervention (PCI). BEST ¼ Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the
Treatment of Patients with Multivessel Coronary Artery Disease trial; EXCEL ¼ Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of
Left Main Revascularization trial; FREEDOM ¼ Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel
Disease trial; GDMT1 ¼ guideline-directed medical therapy 1; PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease trial; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With TAXUS
and Cardiac Surgery trial.
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596Implantation in the Treatment of Patients
with Multivessel Coronary Artery Disease) trial
(30); and
 EXCEL (Evaluation of XIENCE versus Coronary
Artery Bypass Surgery for Effectiveness of Left
Main Revascularization) trial (31).
An additional 2 surgical trials (CORONARY [CABG
Off or On Pump Revascularization Study] [32] and
ART [Arterial Revascularisation Trial] [33]) were
added due to their relevance in the ﬁeld of coronary
revascularization and the availability of data on
medical therapy. These trials were analyzed sepa-
rately because they did not compare PCI versus CABG
(Online Figures 2 and 3, Online Table 1).
STUDY CHARACTERISTICS. The 6 studies included in
this review were all large, multicenter RCTs that
compared PCI versus CABG in patients undergoing
revascularization for complex CAD (Table 1). All those
studies were considered landmark trials that provide
the evidence basis for contemporary practice of cor-
onary revascularization.RISK OF BIAS WITHIN STUDIES. All the studies
included in this review were RCTs of high methodo-
logical quality (Online Table 2).
OVERALL COMPLIANCE WITH GDMT. Figures 1 and 2
illustrate compliance to GDMT1 and GDMT2, respec-
tively, over time in all the trials. Data regarding
individual drug classes are available in Online
Table 3. There was substantial variability between
studies in both GDMT1 and GDMT2, as noted by the
high I2 values at each time point.
COMPLIANCE WITH GDMT IN PCI VERSUS CABG
GROUPS. The Central Illustration and Figure 3 illus-
trate the difference between PCI and CABG in the
proportion of compliance with GDMT1 and GDMT2,
respectively, over time. For all studies except EXCEL
with GDMT1, compliance was higher with PCI than
with CABG. Data regarding individual drug classes are
provided in Online Table 4.
COMPLIANCE WITH GDMT AND CLINICAL
OUTCOMES. Figure 4 illustrates the inverse associa-
tion between the difference in compliance with
FIGURE 3 Compliance With GDMT2, Deﬁned as Any Antiplatelet Agent þ Beta-Blocker þ Statin þ ACE Inhibitor or ARB, for PCI and CABG
-0.05 0 0.05 0.1 0.15 0.2
Difference in Proportion of Compliance (PCI – CABG) 
SYNTAX
Studies (GDMT2 at discharge)
FREEDOM
PRECOMBAT
BEST
EXCEL
Overall (I2 = 60.34 % , p = 0.036)
0.126 (0.080-0.172)
0.036 (–0.009-0.081)
0.096 (0.043-0.149)
0.127 (0.074-0.180)
0.110 (0.065-0.155)
0.098 (0.064-0.132)
299/855
475/947
23/294
63/442
334/911
1,194/3,449
CABG
421/885
512/953
52/298
118/438
444/931
1,547/3,505
PCI
-0.05 0 0.05 0.1 0.15
Difference in Proportion of Compliance (PCI – CABG) 
SYNTAX
Studies (GDMT2 at 3 years)
FREEDOM
BEST
EXCEL
Overall (I2 = 29.73 % , p = 0.244)
0.006 (–0.042-0.055)
0.046 (–0.009-0.102)
0.084 (0.026-0.142)
0.049 (–0.007-0.104)
0.044 (0.011-0.076)
342/780
336/571
53/354
323/616
1,054/2,321
CABG
371/834
386/608
80/342
342/597
11,79/2,381
PCI
-0.05 0 0.05 0.1 0.15 0.2
Difference in Proportion of Compliance (PCI – CABG) 
SYNTAX
Studies (GDMT2 at 5 years)
FREEDOM
BEST
Overall (I2 = 11.71 % , p = 0.402)
0.033 (–0.018-0.084)
0.081 (–0.013-0.175)
0.084 (0.020-0.148)
0.058 (0.018-0.098)
309/715
115/203
12/184
436/1,102
CABG
350/753
134/207
26/174
510/1,134
PCI
0 0.05 0.1 0.15
Difference in Proportion of Compliance (PCI – CABG) 
SYNTAX
Studies (GDMT2 at 1 year)
FREEDOM
PRECOMBAT
BEST
EXCEL
Overall (I2 = 0 % , p = 0.917)
0.085 (0.037-0.132)
0.085 (0.038-0.132)
0.096 (0.040-0.151)
0.079 (0.020-0.139)
0.062 (0.017-0.108)
0.081 (0.058-0.103)
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
Estimate (95% CI)
341/818
454/801
26/291
107/433
427/912
1,355/3,255
CABG
434/865
553/848
54/292
143/438
484/912
1,668/3,355
PCI
Difference in compliance calculated by subtracting proportion of compliance in coronary artery bypass grafting (CABG) from proportion of compliance in percutaneous
coronary intervention (PCI). Abbreviations as in Figures 1 and 2.
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597GDMT1 at 5 years and the difference in clinical out-
comes (all-cause mortality, MI, and a composite
endpoint of all-cause mortality, MI, and stroke) for
clinical trials with 5-year follow-up. As compliance
with GDMT increased in the PCI group relative to the
CABG group, the better outcomes of CABG became
less evident. There was no difference in clinical out-
comes when compliance for PCI exceeded that of
CABG by approximately 8%.
Data for all other trials and time points are avail-
able in Online Table 5. There was no apparentassociation between compliance with GDMT2 and
clinical outcomes.
DISCUSSION
Despite the compelling beneﬁts demonstrated by
GDMT as secondary prevention after coronary revas-
cularization, compliance remains low even in the
tightly controlled environment of clinical trials.
Furthermore, in our study, compliance with GDMT
was higher in patients undergoing PCI compared with
FIGURE 4 Meta-Regression Relating Compliance With GDMT1 (Any Antiplatelet
Agent þ Beta-Blocker þ Statin) at 5 Years and Clinical Trial Outcomes at 5 Years
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(A)Mortality, (B)myocardial infarction (MI), and (C) a composite of death, MI, and stroke.
Only 3 trials were included (SYNTAX, FREEDOM, and BEST) because the others did not
report 5-year outcomes. The x-axis represents the difference in compliance with GDMT1
between PCI and CABG; the y-axis represents the difference in clinical outcomes
between PCI and CABG. As the difference in compliance favoring PCI widens, the
superiority of CABG in terms of clinical outcomes decreases. The p value is for
comparison between PCI and CABG. The size of the circles reﬂects the weight of the
study. Abbreviations as in Figures 1 and 3.
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598patients undergoing CABG, which may skew the
comparison of clinical endpoints between those
revascularization strategies.
OVERALL COMPLIANCE WITH GDMT. Overall
compliance with aspirin and statins was high and
reasonably stable over time, but there was some
variation among trials, with compliance rates ranging
from 75% to 95%. Some of the lack of compliance with
aspirin may be related to intolerance to aspirin and/orconcurrent use of anticoagulation therapy. Nonethe-
less, compliance with at least 1 antiplatelet agent was
close to 100% in most trials throughout follow-up.
Although aspirin intolerance or hypersensitivity can
affect up to 10% of the population, there are currently
rapid desensitization protocols that can be used in
patients requiring dual antiplatelet therapy (34).
Conversely, prevention of aspirin resistance has
justiﬁed consideration of high-dose aspirin (325 mg
daily) instead of low-dose aspirin (81 mg daily), but
its beneﬁts remain uncertain (35).
The differences in the use of adenosine diphos-
phate P2Y12-receptor inhibitors may be related to
whether dual antiplatelet therapy was used and
for how long after revascularization. Considering
the controversy regarding dual antiplatelet therapy
after coronary revascularization (36–38), the signiﬁ-
cant differences between trials are not unexpected,
particularly when considering surgical trials
(CORONARY and ART). Although dual antiplatelet
therapy is recommended after PCI, its beneﬁt
after CABG remains uncertain and is only recom-
mended in speciﬁc circumstances (e.g., off-pump
surgery) (35).
Compliance with beta-blockers and ACE inhibitors/
ARBs was lower and more variable, ranging from 43%
to 80% and 28% to 79%, respectively. These ﬁndings
are in keeping with previous reports from real-world
registries (3). One possible explanation is the fact
that although the efﬁcacy of antiplatelet agents and
statins in reducing cardiovascular events after coro-
nary revascularization has long been recognized
(1,39,40), the advantages of other drug classes have
been established more recently (41) and may vary
according to comorbidities and risk factors. Indeed,
ACE inhibitors/ARBs are not routinely recommended
after CABG unless in the presence of hypertension,
diabetes, left ventricular systolic dysfunction, and
chronic kidney disease (35,41), due to a potential in-
crease in postoperative complications (42). In addi-
tion, controversies regarding the adverse effects of
beta-blockers and statins may inﬂuence prescribing
decisions (43–45).
Variability between trials was also found regarding
compliance with GDMT1 and GDMT2. Although there
was signiﬁcant heterogeneity, even the highest
compliance rates were unsatisfactory, as <40% of the
patients were taking all the guideline-recommended
drugs at 1 year. Furthermore, there was a modest
decline in compliance over time. Although this
outcome has been documented in the real world,
more stable compliance was expected in this study
due to the stricter follow-up required by clinical trial
protocols (46).
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599The underuse of GDMT, particularly after CABG (8),
is likely multifactorial. It may be related to underes-
timation of the importance of GDMT and the
misconception that the value of maintaining GDMT is
reduced once diseased coronary arteries have been
mechanically revascularized with either PCI or CABG
(47–49). In keeping with this, medical therapy is often
neglected in coronary revascularization trials and
hence poorly reported or not even collected at all, as
happened in the recent NOBLE trial (24). On the
contrary, GDMT compliance seemed higher in pa-
tients undergoing PCI than in those treated without
revascularization (50,51), likely because hospital
admission, often precipitated by an acute coronary
event, provided an opportunity to reconsider pre-
scription of cardioprotective medication. The con-
ﬂicting evidence currently available calls for further
studies to elucidate the factors related to GDMT
noncompliance.
Irrespective of the underlying reasons, poor
compliance with medical therapy that has demon-
strated compelling beneﬁts for secondary prevention
in landmark clinical trials is a matter of concern.
Considering that clinical trials operate within a
strictly controlled environment and include a highly
selected population of patients, drug compliance
would be expected to be optimal. Furthermore, clin-
ical trials provide the evidence to support current
clinical practice and emphasize ideal standards.
Therefore, optimizing compliance to GDMT is para-
mount to improve compliance and outcomes in
everyday practice.
COMPARISON OF COMPLIANCE BETWEEN PCI AND
CABG. Compliance with GDMT was consistently
lower for patients undergoing CABG compared with
PCI. The difference was particularly marked for P2Y12-
receptor inhibitors, as dual antiplatelet therapy is
formally recommended in the guidelines after PCI
(41). In contrast, aspirin and statins were identically
used in both groups, and beta-blockers were more
common in the CABG group in the EXCEL trial,
perhaps due to their potential utility in preventing or
treating post-operative atrial ﬁbrillation (52).
Compliance with GDMT1 and GDMT2 was also
better in the PCI group compared with the CABG
group, with a difference close to 10% at 1 year for
GDMT2. The underlying reasons are difﬁcult to
identify. The common although erroneous assump-
tion that more complete revascularization after
CABG obviates the need for further medical therapy
cannot be overlooked. Medical therapy, particularly
antiplatelet agents (53) and statins (54), reduces
platelet activation, endothelial dysfunction,oxidative stress, and inﬂammation, which have all
been associated with the development and pro-
gression of atherosclerosis (55–57), which is itself
the primary mechanism leading to graft failure,
particularly in venous grafts (58). Conversely, the
lower compliance with ACE inhibitors/ARBs may be
based on evidence suggesting that these drugs have
no impact on midterm mortality or recurrent
ischemia after CABG (59). Concerns about the
detrimental effect of ACE inhibitors/ARBs on renal
function and hyperkalemia in the post-operative
period further compound the lower compliance
with these drugs. However, this theory remains
highly controversial (42,60,61), and the beneﬁt of
these drugs after the ﬁrst 3 months has been
compellingly demonstrated (62–64).
Another potential explanation for the low overall
compliance with GDMT and the variability observed
between individual trials is the high cost of medi-
cines. Cost-effectiveness analyses support this pos-
sibility and imply that providing full coverage for
secondary prevention therapy may save lives and
decrease consumption of health care resources
(65,66). Cardiovascular drugs are not easily afford-
able in many countries, particularly in
South America and Southeast Asia. Therefore, in
trials in which standard medication was not pro-
vided by the study team, the low compliance rates
may reﬂect patients’ inability to access expensive
drugs. Although we could not analyze compliance
rates stratiﬁed according to country, the hypothesis
that the high price of cardiovascular medication
signiﬁcantly limits compliance in clinical trials
deserves further investigation.
INFLUENCE OF GDMT ON CLINICAL TRIAL
OUTCOMES. Our data suggest that there is a corre-
lation between the difference in compliance rates
and clinical outcomes when comparing PCI and
CABG at 5 years. The better outcomes achieved with
CABG versus PCI became less obvious as the
compliance with GDMT increased in PCI versus
CABG. Therefore, if compliance rates were identical
in both groups, the superiority of CABG for major
clinical endpoints might have been even more
marked, as part of the beneﬁt of PCI might be
explained by better compliance with GDMT. How-
ever, because the population of patients included in
each trial was different, the inﬂuence of confound-
ing factors cannot be excluded. In addition, the
correlation between GDMT1 and clinical outcomes
was not corroborated by a similar correlation with
GDMT2. Nevertheless, the importance of this hy-
pothesis deserves consideration. Although some
PERSPECTIVES
COMPETENCY IN PRACTICE-BASED LEARNING
AND IMPROVEMENT: Compliance with GDMT in
contemporary clinical trials is suboptimal and lower in
trials of patients undergoing CABG than in those
investigating PCI.
TRANSLATIONAL OUTLOOK: More concerted
efforts are needed to improve compliance with GDMT
among patients participating in clinical trials of
coronary revascularization and to understand the
impact of compliance on the comparative outcomes of
patients undergoing percutaneous or surgical
coronary revascularization.
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600might argue that the varying proﬁles of medical
therapy in PCI and CABG is part of the difference in
the “strategies” of PCI and CABG, a fair and accu-
rate comparison between PCI and CABG cannot be
appreciated unless medical therapies are equalized
with both approaches. Other than for dual anti-
platelet therapy, single antiplatelet treatment,
beta-blockers, and statins seem advantageous irre-
spective of the revascularization strategy.
STUDY LIMITATIONS. In this study, medication pre-
scription was considered as a surrogate for medica-
tion adherence, which may have resulted in
overestimating true compliance rates. Medication
nonadherence is a well-recognized issue in cardio-
vascular disease and may be responsible for approx-
imately 125,000 preventable deaths every year as
only about one-half of the patients consistently take
prescribed medications (67). In addition, in this
study, it was impossible to assess whether treatment
doses were appropriate and to ascertain the reasons
for noncompliance because this factor was not
tracked in any of the randomized trials. Finally, the
meta-regression relating compliance to subsequent
outcomes was based on only 3 studies and compli-
ance data at one point in time, adding imprecision to
the results. We did not have access to individual
patient-level data in the present analysis, which
would have been superior to meta-regression in
linking compliance with outcomes.
CONCLUSIONS
Although GDMT is crucial for patients to derive the
most beneﬁt from coronary revascularization,
compliance was low even in landmark randomized
clinical trials. Moreover, drug compliance was
consistently lower in the CABG group compared with
the PCI group, and this difference may haveinﬂuenced the differences in major clinical
outcomes between groups. Further research is war-
ranted to delineate the extent to which different
rates of compliance with GDMT after PCI compared
with CABG inﬂuence the relative short- and long-
term outcomes with these revascularization
modalities.
The potential consequences of poor compliance
with GDMT on long-term clinical outcomes are sub-
stantial. Therefore, a pressing need exists to develop
effective strategies to improve compliance with life-
saving drugs. Clinical trials have an important role
to play by serving as an example of ensuring
outstanding compliance with GDMT.
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